New study aims to ease agitated delirium in dying cancer patients
NCT ID NCT03743649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well two drugs, haloperidol and lorazepam, can control severe agitation and confusion (delirium) in people with advanced cancer who are in palliative care. About 110 patients will be enrolled to compare different drug approaches. The goal is to improve comfort for patients and reduce stress for their caregivers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DELIRIUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hosptial de Cancer de Barretos
Barretos, São Paulo, 14784, Brazil
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a dissolvable film quiet ICU delirium?
- A cheap blood marker might flag delirium risk in elderly surgery patients
- Can common heart-surgery practices trigger delirium? a 5,600-patient hunt for clues.
- Isolation in hospital may cloud the minds of older patients — a study investigates
- Could wearable sensors spot delirium before doctors do?
- Can we predict brain fog in older women fighting ovarian cancer?